NYSE: NVS
Novartis Ag Stock

NVS Price
$84.14
Fair Value Price
N/A
Market Cap
$194.46B
52 Week Low
$70.67
52 Week High
$99.01
P/E
16.43x
P/B
3.51x
P/S
4.50x
PEG
1.63x
Dividend Yield
15.99%
Revenue
$48.68B
Earnings
$11.73B
Gross Profit Margin
70.40%
Operating Margin
29.53%
Net Profit Margin
24.10%
Debt to Equity
1.13
Operating Cash Flow
$14B
Beta
0.66
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

Zen Score

High
Medium
Low
41
Industry average

Reasons for this score

NVS ($84.14) is trading below its intrinsic value of $260.45, according to Benjamin Graham's Formula from Chapter 14 of "The Intelligent Investor"
Valuation
NVS is good value based on its earnings relative to its share price (16.43x), compared to the US market average 38.92x)
Valuation
NVS is good value based on its earnings relative to its share price (16.43x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

1 of 13

NVS News

Valuation

NVS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
16.43x
Industry
-11.07x
Market
38.92x
NVS is good value based on its earnings relative to its share price (16.43x), compared to the US market average 38.92x)
Valuation
NVS is good value based on its earnings relative to its share price (16.43x), compared to the US Drug Manufacturers - General industry average (-11.07x)
Valuation

NVS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
3.51x
Industry
7.85x
Market
65.04x
NVS is good value based on its book value relative to its share price (3.51x), compared to the US market average (65.04x)
Valuation
NVS is good value based on its book value relative to its share price (3.51x), compared to the US Drug Manufacturers - General industry average (7.85x)
Valuation

NVS price to earnings growth (PEG)

For valuing profitable companies with growth potential
NVS is poor value relative to its rate of earnings growth, measured by PEG ratio (1.63x)
Valuation

NVS's financial health

Profit margin

Revenue
$48.7B
Net Income
$11.7B
Profit Margin
24.10%
NVS's Earnings (EBIT) of $14.38B can safely cover interest payments on company debt ($29.33B)
Financials
NVS's profit margin has decreased (-3.30%) in the last year from (27.40%) to (24.10%)
Financials

Assets to liabilities

Assets
$118.4B
Liabilities
$62.8B
Debt to equity
0.53
NVS's short-term assets ($29.50B) exceed its short-term liabilities ($28.26B)
Financials
NVS's long-term liabilities ($34.56B) exceed its short-term assets ($29.50B)
Financials
NVS's debt has increased relative to shareholder equity (1.13), over the past 5 years ago (0.77)
Financials
NVS's debt to equity ratio (1.13) is considered high
Financials

Cash flow

Operating
$13.6B
Investing
-$2.2B
Financing
-$13.6B
NVS's operating cash flow ($13.63B) is sufficient to service the company's debt ($29.33B)
Financials

Novartis Ag Stock FAQ

(NYSE: NVS) Novartis Ag trades on the NYSE under the ticker symbol NVS. Novartis Ag stock quotes can also be displayed as NYSE: NVS.
(NYSE: NVS) Novartis Ag stock price per share is $84.14 today (as of Oct 21, 2020).
(NYSE: NVS) Novartis Ag's 52-week high was $99.01, and its 52-week low was $70.67. It is currently -15.02% from its 52-week high and 19.06% from its 52-week low.
(NYSE: NVS) Novartis Ag's market cap is $194.46B, as of Oct 22, 2020.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Novartis Ag's market cap is calculated by multiplying NVS's current stock price of $84.14 by NVS's total outstanding shares of 2,311,171,429.
(NYSE: NVS) Novartis Ag currently has 2,311,171,429 outstanding shares. With Novartis Ag stock trading at $84.14 per share, the total value of Novartis Ag stock (market capitalization) is $194.46B.

Novartis Ag stock was originally listed at a price of $40.69 in Dec 31, 1997. If you had invested in Novartis Ag stock at $40.69, your return over the last 22 years would have been 106.81%, for an annualized return of 3.36%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics